

Current Report No 8**Signatory of a cooperation agreement leading to opening of a diagnostic laboratory that utilizes Issuer's products and know-how.**

Management Board of Genomtec S.A. ("the Issuer") hereby announces that as of today, i.e. on April 30, 2021, an agreement was signed between the Issuer and Dolnośląskie Centrum Medyczne Dolmed Spółka Akcyjna headquartered in Wrocław ("Partner", "Dolmed") for the provision of products and services provided by Genomtec (" Agreement"). The cooperation's aim is to commence offering of the laboratory services in the field of genetic diagnostics utilizing the Issuer's products and implementing support of the Issuer to the Partner leading to genetic laboratory premises and workflows organization. The Issuer's support includes the selection and delivery of equipment, staff recruitment, and the creation of operational processes. As part of the agreement, the Parties also agree to cooperate in the field of mutual marketing of products and services.

Dolmed is the largest multidisciplinary healthcare provider in Wrocław and Lower Silesia, offering a wide range of basic and specialist medical services, accepting the Polish National Health reimbursement schedule along with the private reimbursement and individual private (for a fee) walk-ins. Dolmed has a multi-departmental, fully computerized clinic, employing about 200 people, including over 90 medical doctors of various specialties. Every year, the offered services are used by circa 150,000 patients, across various medical procedures, mainly residents of the Wrocław agglomeration.

The selling price of products and services does not differ from the established market standard applied by the Issuer. The Issuer's revenue amount has not been specified in the Agreement and will depend on generated purchase orders, therefore for the Issuer's financial plans it may be of insignificant importance. Nonetheless, the very fact of opening the first partnering laboratory using Issuer's products bears importance due to the current stage of the Issuer's development, confirming commercial feasibility of usage the currently approved diagnostic test kits in the RT-LAMP technique, as well as the commercialization of other developed in the pipeline LAMP-based genetic assays.

The Management Board of the Company considered the action of Agreement seal as confidential information, because the launch of partnering laboratory confirms products' commercial viability, their applicability and inherent benefits therefrom, and thus indicative of, if the above-mentioned Agreement is executed, a potential significant impact on the future income situation of the Issuer, as well as on popularizing the Genomtec technology and products themselves. Therefore, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.